Conor Kirby, DO
Internal Medicine · Albuquerque, NMNPI 1962030080
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $787 of the $1,075 with a category attached, or 73.2%. It is spread thinly across 13 manufacturers, the largest accounting for just 20.8%. Reporting peaked in 2024 at $638 and has fallen 51.0% since, to $313 in 2025.
Across 26 payments — averaging $41.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$224
- AstraZeneca$135
- Exelixis Inc.$124
- Astellas Pharma US Inc$99
- AVEO Pharmaceuticals, Inc.$90
- Gilead$87
- plus $316 from 7 others
What the payments were for
- Food & beverage$78773%
- Education$28827%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 2 | $224 |
| AstraZeneca | 6 | $135 |
| Exelixis Inc. | 1 | $124 |
| Astellas Pharma US Inc | 1 | $99 |
| AVEO Pharmaceuticals, Inc. | 1 | $90 |
| Gilead | 1 | $87 |
| Daiichi Sankyo Inc. | 3 | $74 |
| Beone Medicines USA, Inc. | 3 | $63 |
| Johnson & Johnson | 3 | $50 |
| Beigene USA, Inc. | 2 | $40 |
| Genentech, Inc. | 1 | $36 |
| AbbVie | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,075 in reported general payments places this provider in the 85th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Morphine Sulfate ErMorphine Sulfate | 12 | $1,085 |
| Alendronate Sodium | 22 | $400 |
| Rosuvastatin Calcium | 18 | $273 |
| Metformin Hcl ErMetformin Hcl | 19 | $243 |
| Oxycodone Hcl | 13 | $205 |
| Finasteride | 11 | $162 |
| Levothyroxine Sodium | 12 | $139 |
| Metoprolol Succinate | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Albuquerque
- Edward LewieckiAlbuquerque$491K
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
- Mark WalkerAlbuquerque$24K
- Joao TeixeiraAlbuquerque$18K
- Karla AlmarazAlbuquerque$18K
- David SosaAlbuquerque$11K
- Revati ReddyAlbuquerque$7K
- Ross DavidsonAlbuquerque$7K
- Edmee RodriguezAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.